Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine

Virology Journal

Volumn 8, Issue , 2011, Pages

  Krause, Anja ^a   Xu, Yaqin ^a   Ross, Sara ^a   Wu, Wendy ^a   Joh, Ju ^a   Worgall, Stefan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FORMALIN INACTIVATED RESPIRATORY SYNCYTIAL VIRUS VACCINE; GAMMA INTERFERON; INACTIVATED VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; DRUG CARRIER; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS FUSION PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; VIRUS INACTIVATION; ANIMAL; BAGG ALBINO MOUSE; GENE VECTOR; GENETICS; IMMUNOLOGY; LUNG; REGULATORY T LYMPHOCYTE; SECRETION; T LYMPHOCYTE;

ADENOVIRIDAE; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADENOVIRIDAE; ANIMALS; DENDRITIC CELLS; DRUG CARRIERS; FEMALE; GENETIC VECTORS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS;

EID: 79960862349     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-375     Document Type: Article

References (69)

1. Respiratory syncytial virus and metapneumovirus. Collins PL, Crowe JE Jr, Fields Virology Philadelphia: Lippincott-Williams and Wilkins, Wolters Kluwer Business, Knipe DM, Howley P, 2007 1601 1646
2. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE, Am J Epidemiol 1969 89 405 421 4305197
3. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Am J Epidemiol 1969 89 422 434 4305198
4. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Castilow EM, Olson MR, Varga SM, Immunol Res 2007 39 225 239 10.1007/s12026-007-0071-6 17917067 (Pubitemid 47574888)
5. Immune responses and disease enhancement during respiratory syncytial virus infection. Openshaw PJ, Tregoning JS, Clin Microbiol Rev 2005 18 541 555 10.1128/CMR.18.3.541-555.2005 16020689 (Pubitemid 40995115)
6. A role for immune complexes in enhanced respiratory syncytial virus disease. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. J Exp Med 2002 196 859 865 10.1084/jem.20020781 12235218
7. Immunopathology of RSV infection: prospects for developing vaccines without this complication. van Drunen Littel-van den Hurk, Mapletoft JW, Arsic N, Kovacs-Nolan J, Rev Med Virol 2007 17 5 34 10.1002/rmv.518 17004293 (Pubitemid 46115872)
8. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC III, Murphy BR, J Virol 1994 68 5321 5325 8035532 (Pubitemid 24226607)
9. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG, J Immunol 1993 151 2032 2040 8345194 (Pubitemid 23235675)
10. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN, J Virol 2001 75 12421 12430 10.1128/JVI.75.24.12421- 12430.2001 11711632 (Pubitemid 33115914)
11. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Hussell T, Baldwin CJ, O'Garra A, Openshaw PJ, Eur J Immunol 1997 27 3341 3349 10.1002/eji.1830271233 9464822 (Pubitemid 28018031)
12. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. Hussell T, Openshaw PJ, J Gen Virol 1998 79 Pt 11 2593 2601 9820134 (Pubitemid 28497611)
13. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. Srikiatkhachorn A, Braciale TJ, J Exp Med 1997 186 421 432 10.1084/jem.186.3.421 9236194 (Pubitemid 27332900)
14. CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-Enhanced Disease. Olson MR, Varga SM, The Journal of Immunology 2007 179 5415 5424 17911628
15. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Johnson TR, Graham BS, Pediatr Infect Dis J 2004 23 46 S57 10.1097/01.inf.0000108192.94692.d2 14730270
16. Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism. Johnson TR, Graham BS, J Virol 1999 73 8485 8495 10482601 (Pubitemid 29441712)
17. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. Johnson TR, Rothenberg ME, Graham BS, Journal of Leukocyte Biology 2008 jlb.
18. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Nat Med 2009 15 34 41 10.1038/nm.1894 19079256
19. Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. Castilow EM, Legge KL, Varga SM, J Immunol 2008 181 6692 6696 18981084
20. Immunization against viral respiratory disease: a review. Greenberg HB, Piedra PA, Pediatr Infect Dis J 2004 23 254 S261 10.1097/01.inf.0000144756. 69887.f8 15577581 (Pubitemid 44146421)
21. Clinical experience with respiratory syncytial virus vaccines. Piedra PA, Pediatr Infect Dis J 2003 22 94 S99 12671459
22. Advances in respiratory syncytial virus vaccine development. Kneyber MC, Kimpen JL, Curr Opin Investig Drugs 2004 5 163 170 15043390
23. Respiratory Syncytial Virus Recombinant F Protein (Residues 255-278) Induces a Helper T Cell Type 1 Immune Response in Mice. Singh SR, Dennis VA, Carter CL, Pillai SR, Moore EG, Viral Immunology 2007 20 261 275 10.1089/vim.2007.0008 17603843 (Pubitemid 47076208)
24. Antivector and antitransgene host responses in gene therapy. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG, Curr Opin Mol Ther 2000 2 376 382 11249767 (Pubitemid 30662865)
25. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Zhou D, Ertl HC, Expert Opin Biol Ther 2006 6 63 72 10.1517/14712598.6.1.63 16370915 (Pubitemid 43049347)
26. Evaluation of the protective efficacy of recombinant vaccinia viruses and adenoviruses that express respiratory syncytial virus glycoproteins. Collins PL, Davis AR, Lubeck MD, Mizutani S, Hung PP, Prince GA, et al. Vaccines 90: Modern approaches to new vaccines including prevention of AIDS Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, Brown F, 1990 79
27. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, et al. Biochem Biophys Res Commun 2009 381 528 532 10.1016/j.bbrc.2009.02.075 19233131
28. Immunogenicity and protective efficacy of adenovirus vectored respiratory syncytial virus vaccine. Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, et al. Vaccines 91: Modern approaches to new vaccines including prevention of AIDS Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, Chanock RM, Ginsberg HS, Brown F, Lerner RA, 1991 293 297
29. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, et al. J Infect Dis 1992 166 769 775 10.1093/infdis/166.4.769 1527411
30. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Hsu KH, Lubeck MD, Bhat BM, Bhat RA, Kostek B, Selling BH, et al. Vaccine 1994 12 607 612 10.1016/0264-410X(94)90264-X 8085377 (Pubitemid 24153526)
31. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al. Vaccine 2009 27 5460 5471 10.1016/j.vaccine.2009.07.004 19622401
32. Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection. Yu JR, Kim S, Lee JB, Chang J, The Journal of Virology 2008 82 2350 2357 10.1128/JVI.02372-07 (Pubitemid 351293535)
33. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Dietz AB, Vuk-Pavlovic S, Blood 1998 91 392 398 9427691 (Pubitemid 28053360)
34. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Herrera OB, Brett S, Lechler RI, Vaccine 2002 21 231 242 10.1016/S0264-410X(02)00448-6 12450698 (Pubitemid 35346818)
35. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. Jooss K, Yang Y, Fisher KJ, Wilson JM, J Virol 1998 72 4212 4223 9557710 (Pubitemid 28188726)
36. Adenovirus vector-mediated gene transfer to regional lymph nodes. Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ, Hum Gene Ther 2000 11 759 769 10.1089/10430340050015653 10757355 (Pubitemid 30180280)
37. Distinct Roles of Adenovirus Vector-Transduced Dendritic Cells, Myoblasts, and Endothelial Cells in Mediating an Immune Response against a Transgene Product. Mercier S, Gahery-Segard H, Monteil M, Lengagne R, Guillet JG, Eloit M, et al. The Journal of Virology 2002 76 2899 2911 10.1128/JVI.76.6.2899-2911.2002 (Pubitemid 34184876)
38. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins. Harui A, Roth MD, Vira D, Sanghvi M, Mizuguchi H, Basak SK, J Leukoc Biol 2006 79 1271 1278 10.1189/jlb.1105694 16574766 (Pubitemid 44835562)
39. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, et al. Cancer Res 2001 61 7913 7919 11691812 (Pubitemid 33050987)
40. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, Merritt R, et al. J Virol 2004 78 2572 2580 10.1128/JVI.78.5.2572-2580.2004 14963160 (Pubitemid 38228952)
41. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ, Science 1999 286 1568 1571 10.1126/science.286.5444.1568 10567265
42. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. Wickham TJ, Tzeng E, Shears LL2, Roelvink PW, Li Y, Lee GM, et al. J Virol 1997 71 8221 8229 9343173 (Pubitemid 27446397)
43. Dendritic cell subsets and immune regulation in the lung. de Heer HJ, Hammad H, Kool M, Lambrecht BN, Semin Immunol 2005 17 295 303 10.1016/j.smim.2005.05.002 15967679 (Pubitemid 40981934)
44. Division of labor between dendritic cell subsets of the lung. GeurtsvanKessel CH, Lambrecht BN, Mucosal Immunol 2008 1 442 450 10.1038/mi.2008.39 19079211
45. Antigen presentation by dendritic cells in vivo. Segura E, Villadangos JA, Curr Opin Immunol 2009 21 105 110 10.1016/j.coi.2009.03.011 19342210
46. Immunology taught by lung dendritic cells. von Garnier C, Nicod LP, Swiss Med Wkly 2009 139 186 192 19137454
47. The phenotype and function of lung dendritic cells. Webb TJ, Critical reviews in immunology 2005 25 465 491 16390323 (Pubitemid 44264706)
48. Dendritic cells at the host-pathogen interface. Kelsall BL, Biron CA, Sharma O, Kaye PM, Nat Immunol 2002 3 699 702 10.1038/ni0802-699 12145651
49. Mouse and human dendritic cell subtypes. Shortman K, Liu YJ, Nat Rev Immunol 2002 2 151 161 10.1038/nri746 11913066 (Pubitemid 37336516)
50. The Balance between Plasmacytoid DC versus Conventional DC Determines Pulmonary Immunity to Virus Infections. Smit JJ, Lindell DM, Boon L, Kool M, Lambrecht BN, Lukacs NW, PLoS ONE 2008 3 1720 10.1371/journal.pone.0001720 18320041 (Pubitemid 351891291)
51. The phenotype and function of lung dendritic cells. Webb TJ, Sumpter TL, Thiele AT, Swanson KA, Wilkes DS, Crit Rev Immunol 2005 25 465 491 16390323 (Pubitemid 44264706)
52. Development of dendritic-cell lineages. Wu L, Liu YJ, Immunity 2007 26 741 750 10.1016/j.immuni.2007.06.006 17582346 (Pubitemid 46908964)
53. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. Lambrecht BN, De VM, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA, J Clin Invest 2000 106 551 559 10.1172/JCI8107 10953030 (Pubitemid 30666388)
54. Inhibition of Toll-Like Receptor 7- and 9-Mediated Alpha/Beta Interferon Production in Human Plasmacytoid Dendritic Cells by Respiratory Syncytial Virus and Measles Virus. Schlender J, Hornung V, Finke S, Gunthner-Biller M, Marozin S, Brzozka K, et al. The Journal of Virology 2005 79 5507 5515 10.1128/JVI.79.9.5507-5515.2005 (Pubitemid 40548219)
55. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. Smit JJ, Rudd BD, Lukacs NW, J Exp Med 2006 203 1153 1159 10.1084/jem.20052359 16682497 (Pubitemid 43736586)
56. Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. Wang H, Peters N, Schwarze J, J Immunol 2006 177 6263 6270 17056556 (Pubitemid 44628844)
57. Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. Beyer M, Bartz H, Horner K, Doths S, Koerner-Rettberg C, Schwarze J, J Allergy Clin Immunol 2004 113 127 133 10.1016/j.jaci.2003.10.057 14713917 (Pubitemid 38096172)
58. Subversion of pulmonary dendritic cell function by paramyxovirus infections. Guerrero-Plata A, Kolli D, Hong C, Casola A, Garofalo RP, J Immunol 2009 182 3072 3083 10.4049/jimmunol.0802262 19234204
59. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. Lukens MV, Kruijsen D, Coenjaerts FE, Kimpen JL, van Bleek GM, J Virol 2009 83 7235 7243 10.1128/JVI.00452-09 19420085
60. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. Gill MA, Palucka AK, Barton T, Ghaffar F, Jafri H, Banchereau J, et al. J Infect Dis 2005 191 1105 1115 10.1086/428589 15747246 (Pubitemid 40404369)
61. Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells. Boogaard I, van Oosten M, van Rijt LS, Muskens F, Kimman TG, Lambrecht BN, et al. Immunology 2007 122 65 72 10.1111/j.1365-2567. 2007.02613.x 17472722 (Pubitemid 47222596)
62. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. Ouabed A, Hubert FX, Chabannes D, Gautreau L, Heslan M, Josien R, J Immunol 2008 180 5862 5870 18424705
63. Regulatory T Cells Promote Early Influx of CD8+ T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance Disparities. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS, The Journal of Virology 2009 83 3019 3028 10.1128/JVI.00036-09
64. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, et al. Vaccine 2007 25 7372 7378 10.1016/j.vaccine.2007.08.014 17868959 (Pubitemid 47484016)
65. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia - RSV recombinants or RSV. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, et al. Vaccine 1992 10 475 484 10.1016/0264-410X(92)90397-3 1609551
66. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC III, Sotnikov AV, et al. J Virol 1992 66 7444 7451 1433525
67. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ, J Virol 1996 70 2852 2860 8627759 (Pubitemid 26121897)
68. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B, Vaccine 1999 18 392 397 10.1016/S0264-410X(99) 00257-1 10519927 (Pubitemid 29462594)
69. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Hersh J, Crystal RG, Bewig B, Gene Ther 1995 2 124 131 7719929